Amitriptyline aggravates the fibrosis process in a rat model of infravesical obstruction.

International Journal of Experimental Pathology
Patrícia S de Almeida PradoVicente P C Teixeira

Abstract

Infravesical obstruction (IVO) secondary to benign prostatic hypertrophy can affect up to 50% of men over 50 years old and may cause serious and irreversible alterations throughout the urinary tract, especially in the bladder. Therapeutic approaches are currently limited. Amitriptyline has recently been described as an analgesic, anti-inflammatory and myorelaxant in some experimental models. The objective of this study was to investigate the effects of amitriptyline hydrochloride on the process of fibrosis in a bladder outlet obstruction model in rats. Male Wistar rats were subjected to IVO and studied at intervals of 1 and 14 days postprocedure. The rats were randomly divided into five groups: sham, IVO1-T, IVO1-NT, IVO14-T and IVO14-NT. Bladder tissue was processed for histopathology, immunohistochemistry and RT-PCR. The IVO14 groups presented bladder fibrosis, smooth muscle cell hypertrophy and bladder wall thickening. The IVO14-T group demonstrated a higher intensity of fibrosis, higher macrophage infiltration rate and higher gene expression of Transforming growth factor (TGF) Tgf-β1. Thus this data shows that in this experimental mode amitriptyline had an amplifying effect on the process of fibrosis as a whole.

References

Dec 1, 1982·The Journal of Urology·A Mattiasson, B Uvelius
Apr 1, 1981·British Journal of Urology·R CortivoI Castellani
Mar 16, 1994·Molecular and Cellular Biochemistry·M W ChenR Buttyan
Sep 1, 1996·Endocrinology and Metabolism Clinics of North America·A J D'Ercole
Aug 5, 1999·Kidney International·V OphascharoensukR J Johnson
Dec 5, 2000·Matrix Biology : Journal of the International Society for Matrix Biology·C M Giachelli, S Steitz
Mar 27, 2001·Arthritis and Rheumatism·M G AtturA R Amin
Oct 31, 2001·International Journal of Urology : Official Journal of the Japanese Urological Association·M MongaP Stein
Jan 17, 2002·The Journal of Urology·H A ArafatS Chacko
May 29, 2002·Urology·Brian J FlynnLawrence I Rothblum
Sep 13, 2003·Kidney International·Eduardo AcharNestor Schor
Jun 3, 2004·Journal of Pharmacological and Toxicological Methods·C H Fry
Jun 28, 2005·Current Urology Reports·Chad Huckabay, Victor W Nitti
Oct 12, 2005·The Journal of Urology·Arndt van Ophoven, Lothar Hertle
Oct 22, 2005·Current Urology Reports·Shane Russell, Kevin T McVary
Jan 3, 2006·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Joao L AmaroRenata Montenegro
Apr 19, 2006·In Vitro Cellular & Developmental Biology. Animal·Renata O PereiraLaís Carvalho
Apr 25, 2006·Journal of Dental Research·J SodekR Zohar
Sep 19, 2006·Toxicology and Applied Pharmacology·Norihito KitagawaMasatoshi Morimoto
Oct 6, 2006·Archives of Gynecology and Obstetrics·Ehab Kelada, Amanda Jones
Feb 17, 2007·Acta Pharmacologica Sinica·Li GuXin-Lun Tian
Mar 6, 2007·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Mauricio RubinsteinWaldemar S Costa
Nov 6, 2007·Toxicology·A M Moreno-FernándezP Navas
Jan 29, 2008·Experimental Biology and Medicine·Tatiana Kisseleva, David A Brenner
Nov 18, 2008·International Immunopharmacology·Pamella Huey Mei WangNiels Olsen Saraiva Câmara
Mar 6, 2009·Toxicology and Applied Pharmacology·Mario D CorderoJosé Antonio Sánchez-Alcázar

❮ Previous
Next ❯

Citations

Jan 1, 2021·BioMed Research International·Grzegorz NiemczykAgnieszka Cudnoch-Jedrzejewska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.